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Volume 53, Number 2 Abstracts 5491.83-2.19) for coronary heart disease, 2.27 (95% CI, 1.95-2.65) for isch-
emic stroke, 1.56 (95% CI, 1.9-2.05) for hemorrhagic stroke, 1.84 (95% CI,
1.59-2.13) for unclassified stroke, and 1.73 (95% CI, 1.51-198) for aggre-
gate of other vascular deaths. Adjustments for lipid, inflammatory, or renal
markers did not appreciatively change the HRs. HRs for coronary heart
disease were higher in women than in men, at 40 to 59 years and at 70
years, and for fatal vs nonfatal disease. Assuming an adult population wide
prevalence of 10%, diabetes is estimated to account for 11% (95% CI,
10%-12%) of vascular deaths. There was no significant relationship to
vascular risk for blood glucose concentrations between 3.90 and 5.59
mmol/L. For patients with blood glucose concentrations 3.90 mmol/L,
HRs for coronary heart disease were 1.07 (95% CI, 0.97-1.18), for blood
glucose concentrations between 5.60 and 6.09 mmol/L the HR was 1.11
(95% CI 1.04-1.18), and for those with blood glucose concentrations
between 6.10 and 6.99 mmol/L, the HR was 1.17 (95% CI, 1.08-1.26).
Comment: There are a lot of numbers in this article. When one puts
the numbers in a public health perspective, the analysis is sobering. In
developed countries, 10% of vascular deaths result from diabetes. This
corresponds to an estimated 325,000 deaths per year. Results do not change
after adjustment for lipid, inflammatory, or renal markers. This means the
burden of vascular deaths will continue to increase as diabetes prevalence
continues to increase and this will happen even if cigarette smoking decreases
and there are further improvements in management of other vascular risk
factors. It is also important to note the increased burden of vascular disease
in patients with modestly elevated blood glucose concentrations that do not
meet the definition of diabetes mellitus. The ever-expanding obesity epi-
demic (no pun intended) will result in many hundreds of thousands of
diabetes related deaths over the next decade.
Effectiveness of Combination of Losartan Potassium and Doxycycline
versus Single-Drug Treatments in the Secondary Prevention of Tho-
racic Aortic Aneurysm in Marfan Syndrome
Yang HHC, Kim JM, Chung E. J Thorac Cardiovasc Surg 2010;140:
305-12.
Conclusion: The combination of losartan potassium and doxycycline
synergistically offers better aneurysm-suppressing effect in a mouse model of
Marfan syndrome than does either drug alone.
Summary: Marfan syndrome is autosomal dominant and results from
mutations in the gene encoding fibrillin-1. Abnormal aortic elastic fibers
result in altered load-bearing capacity of the aorta with degeneration,
fibrosis, and microdissection. Progression of thoracic aortic aneurysm in
Marfan syndrome is associated with upregulation of matrix metalloprotein-
ases (MMPs)-2 and MMP-9. Doxycycline inhibits MMP-2 and MMP-9
production and provides aneurysm suppressing effects in a mouse model of
Marfan syndrome (Chung AW, Circ Res 2006;99:140-8). Perturbations of
transforming growth factor (TGF)-may also contribute toMarfan syndrome.
TGF- can be antagonized with losartan potassium, an angiotensin-2 type-1
receptor antagonist. The authors hypothesize a combination of losartan potas-
sium and doxycycline would offer enhanced inhibition of aortic degeneration in
Marfan syndrome. A mouse model of Marfan syndrome (Fbn1C1039G//L)
was used in this study. Mice at 4 months of age, when aneurysm had been
established, were given doxycycline alone (0.24 g/L), losartan potassium alone
(0.6 g/L), or a combination of 0.12 g/L doxycycline and 0.3g/L losartan
potassium in drinking water. Littermate Fbn1/ mice served as controls.
Thoracic aortas were harvested and studied at 6 and 9 months.
Aortic diameter at 9 months increased in the untreated group by 40%
relative to controls. The aortic diameter was reduced by 10% in losartan
potassium-treated mice and by 16% in doxycycline-treated mice compared
with untreated aortas. Combination losartan potassium and doxycycline
completely prevented thoracic aortic aneurysm in the mouse model. There
was improvement in elastic fiber organization with downregulation of
MMP-2 and MMP-9, as well as downregulation of TGF-. Aortic contrac-
tile and relaxation functions also normalized compared with control values.
Comment: Combination drug treatment in a mouse model of Marfan
syndrome appears to offer potentially extraordinary secondary prevention
benefits. Although the mouse model may not be representative of all cases of
Marfan syndrome in humans, the mutation in the model is the most
common mutation in classic Marfan syndrome. Both drugs used for second-
ary prevention in this study are readily available, and it seems a human study
of combination therapy for prevention of aortic degeneration in patients
with Marfan syndrome should not be long off.
Venous and Cerebrospinal Fluid Flow in Multiple Sclerosis: A Case-
Control Study
Sundstrom P, Wahlin A, Ambarki K, et al. Ann Neurology 2010;68:255-9.
Conclusion: This study does not provide evidence confirming the
suggested vascular multiple sclerosis (MS) hypothesis.
Summary: The MS chronic cerebral spinal venous insufficiency hy-
pothesis suggests MS may develop secondary to impaired venous outflow
from the central nervous system (CNS). The implication is that stenosis of
8
1he veins draining the cerebral circulation may be potentially treated with
atheter-based techniques and lead to symptom improvement in patients
ith MS. Zamboni et al has reported stenoses of the veins draining the
erebral circulation are common in patients with MS and are basically never
een in those without MS (J Neurol Sci 2009;282:21-7). The hypothesis is
erebral venous insufficiency leads to accumulation of iron in the CNS and
riggers autoimmune events leading to MS. This possible link between MS
nd reported chronic cerebral spinal venous insufficiency is not generally
ccepted by MS neurologists at this time (Khan O, et al, Ann Neurol
010;67:286-90). In this current study, the authors used magnetic reso-
ance imaging (MRI) with phase contrast to evaluate flow direction of
ntercranial blood flow. Blood flow of the internal carotid arteries, the
ertebral arteries, and the internal jugular (IJ) veins as well as the anatomy of
he vessels was assessed in 21MS patients and 20 healthy controls usingMRI
hase-contrast imaging. Cases and control were matched for age (mean, 31
ears). There were 13 women and 8 men in theMS group and 8 women and
2 men in the control group. Patients with MS had a median duration of
isease of 5 years (range, 1-25 years).
The authors found no significant differences between controls and
atients with MS with respect to total IJ blood flow, the fraction of cerebral
lood flow returning through both IJ veins or either IJ vein, the prevalence
f IJ vein reflux, or any studied cerebrospinal fluid flow parameter. There
ere no significant differences between sexes for any parameter. Cases and
ontrols that had reflux both had markedly decreased IJ vein blood flow on
he effected side. A decreased blood flow fraction in one of the IJ veins was
enerally accompanied by compensatory increase of contralateral IJ vein
lood flow. In the 21 patients withMS, contrast-enhancedMR angiography
evealed no signs of venous stenosis in 18 patients and venous stenosis in 3.
ll stenosis were located in the middle portion of the IJ vein, and these
atients with stenosis had a corresponding decreased IJ vein flow as mea-
ured by phase-contrast MRI. The authors could find no typical pattern of
he IJ vein blood flow in the patients with MS.
Comment: The chronic cerebral spinal venous insufficiency hypothesis
s an etiology of MS has captured the attention of the medical community
nd, most especially, MS patients. This report is in sharp contrast with the
ndings of Zamboni et al (J Vasc Surg 2009;50:1348-53), in that the
uthors here are unable to demonstrate differences between cerebral spinal
enous drainage betweenMS cases and controls. The data here make it seem
ikely that any association between chronic cerebral spinal venous insuffi-
iency and MS will be weaker than previously reported. The study does not
rovide support for endovascular treatment of patients with MS. The MS
ommunity, neurologists, and all vascular interventionalists need to develop
rational and deliberate approach to assessment of this new hypothesis. At
his point it seems irresponsible, and perhaps unethical, for physicians to
ncourage expensive and, likely uncovered by insurance, endovascular treat-
ent of the highly vulnerable MS population.
ondaparinux for the Treatment of Superficial-Vein Thrombosis in the
egs
ecousus H, Prandoni P, Mismetti P, and the CALISTO Study Group. N
ngl J Med 2010;363:1222-32.
Conclusion: Fondaparinux is effective in the treatment of patients with
ymptomatic acute superficial venous thrombosis (SVT) of the legs.
Summary: Patients with isolated SVT may develop more serious
anifestations of venous thrombosis, with an 8.3% incidence of symptom-
tic venous thromboembolic (VTE) complications at 3 months and an
stimated 3% to 4% risk of deep venous thrombosis (DVT) or pulmonary
mbolism (PE; Decousus H, et al, Ann Intern Med 2010;152:218-24). To
elp clarify pharmacologic treatment of SVT, the authors conducted the
omparison of Arixtra and Lower Limb Superficial Vein Thrombosis With
lacebo (CALISTO) trial evaluating the efficacy of fondaparinux in reducing
ymptomatic VTE complications, or death, in patients with acute isolated
VT of the legs. There were 3002 patients with SVT 5 cm in length
ssigned to receive fondaparinux (2.5 mg subcutaneously, once daily) or
lacebo for 45 days. This was a randomized double-blind trial. Exclusion
riteria included concurrent DVT, known pulmonary embolism, SVT asso-
iated with sclerotherapy, SVT 3 cm of the saphenofemoral junction, a
revious SVT3months, or previous DVT or PE6months, patients with
condition predisposing to bleeding, or if they had major surgery within the
revious 3 months. Death from any cause, symptomatic PE, symptomatic
VT, symptomatic extension to the saphenofemoral junction, or symptom-
tic recurrence of SVT at day 47 all served as a composite primary end point.
he main safety outcome was major bleeding. Patients were monitored for
7 days.
Any component of the primary end point occurred in 13 of 1502
atients (0.9%) in the fondaparinux group and in 88 of 15,000 patients
5.9%) in the placebo group (relative risk reduction with fondaparinux, 85%;
5% confidence interval, 74%-92%; P  .001). All components of the
rimary efficacy end point were significantly reduced in the fondaparinux
roup with the exception of death (0.1% in both groups). PE or DVT was
5% lower in the fondaparinux group than in the placebo group (0.2% vs
.3%; 95% CI, 50-95%; P  .001). Based on relative risk reductions, 88
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February 2011550 Abstractspatients would need to be treated to prevent one episode of PE or DVT.
Serious adverse events were 0.7% with fondaparinux, and 1.1% with placebo,
with major bleeding occurring in one patient in each group.
Comment: The number needed to treat, based on relative risk reduc-
tion, demonstrated in the trial to prevent one episode of PE with fondapa-
rinux in patients with SVT is 300. This is similar to the number needed to
treat with low-molecular-weight heparin compared with placebo or no
treatment in trials of VTE prophylaxis in acutely ill medical patients (345,
Dentali F, Ann Intern Med 2007;146:278-88). Treatment with fondapa-
rinux also reduced the risk of symptomatic recurrence of SVT and extension
to the saphenofemoral junction. Because both of these events may result in
escalation of therapy, these end points are clinically relevant. Overall, the
data indicate that with pharmacologic therapy it is possible to improve
the natural history of SVT. Cost effectiveness and effects on quality of life
of the 45-day treatment regimen of fondaparinux for SVT will need to
be evaluated both with respect to the cost of fondaparinux and the cost of
diagnostic testing to determine eligibility for treatment.
Long-Term Outcome of Symptomatic Severe Ostial Vertebral Artery
Stenosis (OVAS)
Karameshev A, Schroth G, Mordasini P, et al. Neuroradiology 2010;52:
371-9.
Conclusion: Vertebral artery stenting can be performed with minimal
periprocedural complications. Potential benefits are most likely in those with
bilateral vertebral artery stenosis.
Summary: About 25% of all strokes are posterior circulation strokes
(Bogousslavsky J, Stroke 1988;19:1083-92). Of posterior circulation
strokes, 20% to 25% are associated with a severe ostial stenosis or occlusion
of the vertebral artery (Wityk RJ et al, Arch Neurol 1998;55:470-478).
c
rndovascular management of vertebra artery stenosis is infrequently re-
orted. The only randomized trial, The Carotid and Vertebral Artery
ransluminal Angioplasty Study (CAVATAS, Coward LJ, Stroke 2007;38:
526-1530), enrolled only 16 patients with vertebral artery stenosis. An
dditional trial, the Vertebral Artery Stenting (VAS) trial, may be underway
Trials 2008;9:65). Results are unlikely to be available for many years.
In this study by Karameshev et al, 39 consecutive patients with a
ecently symptomatic (48 hours) severe (70%) ostial vertebral artery
tenosis were evaluated in a single-institution study. Treatment of patients
as medical (n 29) or by vertebral artery stenting (n 10) and was left to
he discretion of the treating physician. Mean follow-up was 2.8 years. Data
ere analyzed using the Kaplan-Meier method for risk of recurrent stroke,
ransient ischemic attack (TIA), or death. Stented patients were younger and
ore likely to have bilateral vertebral artery disease (P  .04 and P  .02).
ertebral artery stenting was successful in all 10 patients. One patient had a
eriprocedural transient ischemic attack. There was restenosis of one verte-
ral artery stent at 9 months. At 4 years of follow-up there was no statistical
ifference in the risk of a combined end point of TIA and stroke in the
osterior circulation in stented (10%) compared with medically treated
atients (45%; relative risk, 0.24; 95% confidence interval, 0.031-1.85; P 
095). Patients with bilateral vertebral disease had 0% recurrence of symp-
oms after stenting at 4 years compared with 91% for medical treatment
relative risk, 0.10; 95% confidence interval, 0.022-0.49; P  .004).
Comment:The study was not randomized and the patients were highly
elected for treatment. Clearly, the study does not provide sufficient data to
ustify a widespread approach to endovascular management of vertebral
rtery stenosis. Medical management remains the mainstay for patients with
ymptomatic vertebral artery stenosis with intervention by open or endovas-
ular techniques reserved for highly selected patients using what amounts to
eally no more than “best guess” criteria.
